2025/08/01 by Anne Huibers, Andrew Wong, Mark C. Burgmans +5 · 1 voice
Medicine · Biochemistry, Genetics and Molecular Biology · #Ocular Oncology and Treatments #Retinal Development and Disorders #Corneal Surgery and Treatments
paper · pdf · doi:10.1093/bjs/znaf130
openalex publication_date 2025/08/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28
Uveal melanoma is the most common primary intraocular malignancy in adults, with distinct genetic and clinical characteristics compared with cutaneous melanoma. Despite improvements in the treatment of the primary tumour, nearly half of the patients will develop distant metastases, most commonly in the liver. Once metastases are detected, the median overall survival is approximately 1 year, with a 2-year survival rate of only 8%. Systemic treatment, including chemotherapy, immunotherapy, and targeted therapy, has historically shown limited efficacy. The first (and so far only) systemic treatment to demonstrate an improvement in overall survival is tebentafusp, which is now approved for treatment of patients with metastatic or unresectable uveal melanoma and an HLA-A*02:01 genotype. Liver-directed therapies include surgical resection, radioembolization, chemoembolization, immune-embolization, isolated hepatic perfusion, and percutaneous hepatic perfusion. This review discusses the clinical background of uveal melanoma and liver metastasis, the efficacy of systemic and locoregional treatment options, and the promising development of combining locoregional liver-directed treatment with systemic treatment.